Overview
First In Human Study Of Increasing Oral Doses Of PF-04634817
Status:
Completed
Completed
Trial end date:
2010-09-01
2010-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The study will evaluate the hypothesis that at doses and plasma concentrations which affect pharmacodynamic markers of activity at the chemokine receptors, CCR2 and CCR5, the compound is safe and well tolerated. It will also evaluate the hypothesis that the pharmacokinetic profile is robust and consistent with a once or twice a day therapeutic administration.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Pfizer
Criteria
Inclusion Criteria:- Healthy male or female (of non-child bearing potential) subjects between 18 and 55
years of age.
- Body mass index of 17.5 to 30.5 kg/m2 and total body weight > 50kg.
Exclusion Criteria:
- Evidence or history of any clinically significant disease.
- Treatment with an investigational drug within 30 days of study start
- Use of prescription and non-prescription medicines within 7 days of study start